Isoniazid is recommended for prevention of tuberculosis (TB) in HIV-infected adults, but its efficacy in children living with HIV (CLHIV) is not known. We performed a systematic review to assess the efficacy of isoniazid for the prevention of TB in CLHIV. Methods: We searched PubMed, Cochrane Clinical Trial Registry and Google Scholar from inception to December 2016. Any randomized controlled trial assessing the role of isoniazid for the prevention of TB in CLHIV was eligible for inclusion. The primary endpoint was TB incidence; secondary end points were mortality, overall survival and severe adverse events. Dual independent extraction of all data was performed. Data were pooled under a random effects model and summarized either as risk ratio (RR) or hazard ratio along with 95% confidence intervals (CIs). Results: Of 931 references, 3 randomized controlled trials enrolling 977 patients met the inclusion criteria. Pooled results showed a statistically nonsignificant reduction in TB incidence (RR: 0.70; 95% CI: 0.47-1.04; P = 0.07) and mortality (RR: 0.94; 95% CI: 0.39-2.23; P = 0.88) with the use of isoniazid compared with placebo. One study was stopped early because of excess deaths in the placebo arm. However, results from subgroup analysis restricted to only completed trials did not change the overall findings. Conclusions: Isoniazid did not reduce the incidence of TB in CLHIV. All included studies were performed in regions with high prevalence of TB making the overall generalizability limited.
A n estimated 6%-10% tuberculosis (TB) cases globally occur in children, while in high disease burden countries, childhood TB accounts for about 15%-20% of all TB cases. 1, 2 Worldwide, in the year 2014, around 1 million children were infected with TB and 140,000 children died of either TB or related complications. 1, 2 While children are at a higher risk of progressing to active disease and developing more severe forms of TB (eg, meningeal and disseminated TB) when compared with adults, some children exposed to TB may harbor latent infection for years and not develop disease until adulthood. 3, 4 The emergence of HIV and its associated immunosuppression has led to an increase in incidence and prevalence of TB. The risk of developing TB is 26-31 times higher in HIV-infected subjects compared with those without HIV. 5 According to the 2013 estimates, 1 in 4 TB deaths globally was associated with HIV. 5 The convergence of these 2 epidemics wreaks havoc in high-prevalence settings. The incidence of TB in children living with HIV (CLHIV) is declining with the use of antiretroviral therapy. However, TB rates in HIV-infected patients still remain high when compared with the HIV-uninfected population. 6 The risk of latent TB is 8-to 10-fold higher among HIVinfected patients when compared with HIV-uninfected subjects. 7, 8 The complex interaction between HIV and TB includes mutual exacerbation of disease severity; hence, it is very important to identify infection and prevent reactivation of latent TB in HIV-infected patients to prevent associated morbidity and mortality. 8 Isoniazid has the potential to prevent TB in HIV patients. Many studies support the role of isoniazid for prevention of TB in adults, but its role in prevention of TB in children is not clear. [9] [10] [11] [12] [13] [14] Treatment guidelines for TB by the World Health Organization (WHO), published in 2011, recommended isoniazid for adults and adolescents living with HIV. However, the guidelines panel also acknowledged the lack of conclusive evidence regarding the role of isoniazid for prevention of TB in CLHIV and the recommendation for the use of isoniazid in children was based on findings in adults. 2 Furthermore, a systematic review and meta-analysis found isoniazid to be beneficial as prophylactic therapy for TB in children. 15 A previous systematic review assessing the role of isoniazid for prevention of TB specifically in CLHIV concluded that isoniazid reduced TB incidence and death. 16 Since then additional studies have been published, warranting a reevaluation of the potential benefit and harms of isoniazid for the prevention of TB in CLHIV. The objective of this systematic review is to synthesize all available evidence regarding the efficacy and safety of isoniazid for prevention of TB in CLHIV.
METHODS
The systematic review was performed as per the methodology documented a priori in a protocol.
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Eligibility Criteria
Any randomized controlled trial (RCT) assessing the role of isoniazid versus any comparator in CLHIV regardless of publication or language status was eligible for inclusion. Any RCTs that had mix of adult and pediatric subjects and reported data separately for pediatric subjects were also eligible for inclusion. 
Study Selection
Two authors (J.C. and A.K.) reviewed titles and abstracts of references retrieved from the searches independently against predefined inclusion criteria. All disagreements about the selection of studies were resolved by consensus accomplished through a joint meeting involving the third author (T.R.).
Outcomes
The primary outcome of this systematic review was the incidence of TB. Secondary outcomes were time to TB (time to event), mortality, overall survival (time to event) and any adverse events.
Data Extraction and Management
Two review authors (J.C. and A.K.) independently extracted data from included trials using a standardized data extraction form. Disagreements were resolved by consensus. Data were extracted on study characteristics (study design, inclusion/exclusion criteria, number randomized, study duration), participants (age, gender), treatment and comparison (dose and administration), risk of bias using Cochrane tool for randomized trials 18 and outcomes (mortality, survival, time to TB onset and moderate to severe adverse events). In addition, we assessed the overall quality of evidence for each outcome according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guidelines, which classify evidence as either very low, low, moderate or high.
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Summary Measures and Synthesis
Data on similar outcomes were pooled under the random effects model. Time to event outcomes (eg, overall survival and time to TB) were summarized as hazard ratio (HR) along with 95% confidence intervals (CIs). Binary outcomes (eg, incidence of TB) were summarized as relative risk (RR) along with 95% CI. The I 2 measure was used for the assessment of heterogeneity among pooled studies, and the same measure was used to assess for a test of interaction in subgroup analyses. 20 We considered an I 2 > 50% as high heterogeneity. All analyses were performed using Review Manager (RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. 21 The summary of findings table was generated using GRADEpro GDT: GRADEpro Guideline Development Tool, Evidence Prime, Inc. 22 The study was performed and reported per the PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, Supplemental Digital Content, http:// links.lww.com/INF/C920.
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Additional Analyses
Additional subgroup and sensitivity analyses were planned according to the differences in patient population, intervention, comparator and risk of bias characteristics. For all subgroup/sensitivity analysis, a test of interaction was also assessed. We also planned for assessment of publication bias. 24 However, because of the availability of a limited number of studies (<10), we did not perform a formal assessment of publication bias.
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RESULTS
Study Selection and Characteristics of Included Studies
The process of selection of eligible studies is illustrated in Figure 1 . The initial search yielded 931 citations of which 3 RCTs met the inclusion criteria. [12] [13] [14] The characteristics of the included studies are summarized in Table 1 . All RCTs enrolled CLHIV 8 weeks old and older with no known history of TB and were performed in South Africa except the study by Zar et al 13 which enrolled children with confirmed or probable TB but isoniazid was started only after the completion of standard TB treatment. The median follow-up was 5.7 months in the study by Zar et al, 13 24 months in the study by Madhi et al 12 and 24 months in the study by Gray et al. 14 The primary outcome was mortality in the study by Zar et al, 13 TB-free survival in the studies by Madhi et al 12 and Gray et al. 14 The sample sizes ranged from 167 to 548. All subjects were prescribed cotrimoxazole for Pneumocystis jirovecii pneumonia prophylaxis, and isoniazid was administered at a dose of 10-20 mg/kg for TB prevention. The study by Zar et al 13 was conducted in the pre-antiretroviral treatment (ART) era, and only 9% of participants received ART at enrollment. In the study by Gray et al, 14 all participants received ART and 31.5% of the subjects received ART at or before enrollment. The study by Zar et al 13 was stopped early because of excess deaths in the placebo arm. To address the issue of early stopping, we performed additional subgroup analysis according to stopping time.
Definition of TB
The diagnosis of TB was based on clinical symptoms in combination with findings on chest radiography, acid-fast staining of sputum, gastric aspirates or specimens from other sources and culture.
Risk of Bias Within Studies
Authors' judgment for each risk of bias element is illustrated in Figure 2 . Overall, the methodologic quality of included studies as per the GRADE method ranged from low to very low (Table 2) . Briefly, all trials reported randomization sequence generation, described dropouts and withdrawals and performed the analysis according to intention-to-treat principle. Description of allocation concealment and blinding of participants was unclear in the trial by Madhi et al.
Incidence of TB
The incidence of TB, extractable from all 3 RCTs (977 patients) (Fig. 3A) , was not statistically significantly different between the isoniazid and placebo groups (RR: 0.70; 95% CI: 0.47-1.04; P = 0.07). The observed heterogeneity between pooled studies was low (I 2 = 2%). In the subgroup analysis, there was no statistically significant difference in the incidence of TB with the use of isoniazid versus placebo (RR: 0.38; 95% CI: 0.14-1.04; P = 0.06) in the trial stopped early (1 RCT; N = 263) 13 or in the trials with complete follow-up (2 RCTs; 714 patients 12, 14 ; RR: 0.78; 95% CI: 0.51-1.18; P = 0.24; I 2 = 0%). The test for interaction between subgroups was not statistically significant (P = 0.20; I 2 = 40%; see Fig. 3A ).
Time to TB
Time to TB, extractable from all 3 RCTs (977 patients), was not statistically significantly different between the isoniazid and placebo groups (HR: 0.56; 95% CI: 0.29-1.09; P = 0.09). The heterogeneity among studies was moderate (I 2 = 45%; see Fig. 3B ). In the subgroup analysis, time to TB was significantly shorter with isoniazid versus placebo in the trial that was stopped early (1 RCT; N = 263; HR: 0.28; 95% CI: 0.10-0.78; P = 0.02) 13 but not in the trials that had complete follow-up (2 RCTs; 714 patients; HR: 0.77; 95% CI: 0.49-1.19; P = 0.04; I 2 = 0%). 12, 14 The test for interaction between subgroups was not statistically significant (P = 0.08; I 2 = 68%; see Fig. 3B ).
Mortality
Mortality, extractable from 3 RCTs (977 patients), was not statistically significantly different between isoniazid and placebo groups (RR: 0.94; 95% CI: 0.39-2.23; P = 0.88). Heterogeneity between pooled trials was high (I 2 = 58%; see Fig. 4A ). 12 to determine whether allocation concealment was adequate. Furthermore, it was unclear how blinding of outcome assessors and patients was accomplished. †The study by Zar et al 13 was stopped early due to high incidence of deaths in the placebo arm and the results favored the isoniazid (although not statistically significant). However, the results from other 2 trials favored the placebo treatment (not statistically significant). ‡The results were associated with wide CIs. §Two RCTs reported statistically nonsignificant results, the trial by Zar et al 13 that was stopped early reported statistically significant findings. ¶The trial by Madhi et al 12 reported no difference between isoniazid and placebo. However, the trend favored placebo. The trial by Zar et al 13 showed a statistically significant benefit in favor of isoniazid.
║Out of 3 RCTs, only 2 reported this outcome. **The results from trial that was stopped early favored isoniazid. However, the pooled results from 2 randomized trials that had complete follow-up favored the placebo.
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. The findings from the subgroup analysis showed that there was no statistically significant difference in mortality with the use of isoniazid versus placebo (RR: 0.52; 95% CI: 0.26-1.03; P = 0.06) in the study with early termination (1 RCT; N = 263) 13 as well as in pooled results from trials with complete follow-up (2 RCTs; N = 714; RR: 1.45; 95% CI: 0.77-2.71; P = 0.25; I 2 = 0%). 12, 14 The test for interaction between subgroups was statistically significant (P = 0.03; I 2 = 78%; see Fig. 4A ).
Overall Survival
Data on overall survival were extractable from only 2 RCTs (810 patients). 12, 13 There was no statistically significant difference in survival between the isoniazid and placebo groups (HR: 0.89; 95% CI: 0.25-3.17; P = 0.86). The heterogeneity between pooled studies was high (I 2 = 85%; see Fig. 4B ). In the subgroup analysis, there was a statistically significant survival benefit with the use of isoniazid versus placebo in the study that stopped early (1 RCT; 263 patients; HR: 0.46; 95% CI: 0.22-0.96; P = 0.04). 13 However, the difference in overall survival was not statistically significant in the study with complete follow-up (HR: 1.68; 95% CI: 0.86-3.28; P = 0.13). The test for interaction between subgroups was statistically significant (P = 0.01; I 2 = 85%; see Fig. 4B ).
Adverse Events
There was no statistically significant difference in the incidence of adverse events, available from all 3 RCTs (977 patients), with isoniazid versus placebo (RR: 1.27; 95% CI: 0.88-1.83; P = 0.20). Heterogeneity between trials was low (I 2 = 2%; Fig. 5) .
The results from subgroup analysis showed no statistically significant difference in moderate to severe adverse events in the study with early stopping (RR: 0.62; 95% CI: 0.21-1.85; P = 0.39) 13 as well as in pooled results from studies with complete follow-up (RR: 1.39; 95% CI: 0.96-2.01; P = 0.08; I 2 = 0%). 12, 14 The test for interaction between subgroups was not statistically significant (P = 0.17; I 2 = 47%; see Fig. 5 ). The most commonly reported moderate to severe adverse events were hematologic events, infections and hepatotoxicity. months of age but not for children below 12 months of age. It is worth noting that chances of progression from Mycobacterium tuberculosis infection to the development of TB disease are higher in the first 2 years of life. 26 Therefore, if isoniazid prophylaxis is not effective in children under 12 months of age, it is unclear why it would be effective in children over 12 months of age. Another possibility is that isoniazid is not effective for primary prevention in infants, the focus of the study by Madhi et al 12 ; however, it may be effective in preventing mortality and progression in children >12 months of age. Infants have more rapid progression of HIV disease, harder to diagnose TB and high overall mortality, and therefore, it is difficult to demonstrate clear efficacy. However, these findings point more toward the inconclusive nature of evidence associated with efficacy of isoniazid for prevention of TB in CLHIV, which needs further testing and warrants review of existing recommendations.
This systematic review also has limitations. While we followed the recommended methodologic rigor in the field to perform this systematic review, the findings are limited by the availability of only 3 RCTs with moderate to high heterogeneity. Furthermore, all these RCTs were conducted on the African continent, in regions with high prevalence of TB making the overall global generalizability limited. Despite limitations, the results of this systematic review are in line with a previous systematic review assessing the role of isoniazid in HIV-infected adults for prevention of TB. The results from the systematic review by Akolo et al 27 also concluded that isoniazid is not helpful for the prevention of primary TB in adult HIV patients.
In summary, results from this systematic review and metaanalysis show that evidence for isoniazid as an effective regimen for prevention of TB in CLHIV is inconclusive at best and emphasizes on the need for a large RCT to detect a clinically meaningful difference. For example, on the basis of results from this systematic review, to observe a reduction in the incidence of TB from 11% to 8% with 80% power at 5% significance, a RCT would need about 3000 subjects. Until then, it would be advisable to revisit the available inconclusive evidence and potentially provide additional guidance for the use of isoniazid in the prevention of TB in HIV-infected children.
